Evidence map›Paper›PMID 29546346›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018

Dynamics of Afebrile Plasmodium falciparum Infections in Mozambican Men.

Beatriz Galatas, Helena Martí-Soler, Lidia Nhamussua, Pau Cisteró, Pedro Aide, Francisco Saute, Clara Menéndez, N Regina Rabinovich, Pedro L Alonso, Quique Bassat and 1 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02698748 (Evaluating the Potential Role of Chloroquine in Preventing Infections During Elimination Campaigns), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02698748 phase2 / phase3completednot on this map

Evaluating the Potential Role of Chloroquine in Preventing Infections During Elimination Campaigns: A Randomized, Single-blind, Placebo-controlled Trial in Asymptomatic Mozambican Adults

TypeinterventionalSponsorCentro de Investigacao em Saude de ManhicaRan2015 to 2015Enrolled75ConditionsMalariaArmsChloroquine, Placebo
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Observational
  6. Ultralow-density Plasmodium falciparum Infections in African Settings.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Beatriz GalatasCentro de Investigação em Saúde de Manhiça, Maputo, Mozambique.
Helena Martí-SolerCentro de Investigação em Saúde de Manhiça, Maputo, Mozambique.
Lidia NhamussuaCentro de Investigação em Saúde de Manhiça, Maputo, Mozambique.
Pau CisteróISGlobal, Barcelona Center for International Health Research, Hospital Clínic-Universitat de Barcelona, Spain.
Pedro AideCentro de Investigação em Saúde de Manhiça, Maputo, Mozambique.
Francisco SauteCentro de Investigação em Saúde de Manhiça, Maputo, Mozambique.
Clara MenéndezCentro de Investigação em Saúde de Manhiça, Maputo, Mozambique.
N Regina RabinovichISGlobal, Barcelona Center for International Health Research, Hospital Clínic-Universitat de Barcelona, Spain.
Pedro L AlonsoCentro de Investigação em Saúde de Manhiça, Maputo, Mozambique.
Quique BassatCentro de Investigação em Saúde de Manhiça, Maputo, Mozambique.
Alfredo MayorCentro de Investigação em Saúde de Manhiça, Maputo, Mozambique.
Manhiça Health Research Centre · MZUniversitat de Barcelona · ESBarcelona Institute for Global Health · ESInstitució Catalana de Recerca i Estudis Avançats · ESMinistry of Health · MZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Afebrile Plasmodium falciparum infections usually remain undetected and untreated in the community and could potentially contribute to sustaining local malaria transmission in areas aiming for malaria elimination. Methods: Thirty-two men with afebrile P. falciparum infections detected with rapid diagnostic test (RDTs) were followed for 28 days. Kaplan-Meier estimates were computed to estimate probability of parasite positivity and of reducing parasitemia by half of its initial level by day 28. Trends of parasite densities quantified by microscopy and real-time quantitative polymerase chain reaction (qPCR) were assessed using Poisson regression models, and the microscopy-to-qPCR positivity ratio was calculated at each time point. Three survival distributions (Gompertz, Weibull, and gamma) were used to evaluate their strength of fit to the data and to predict the median lifetime of infection. Results: The cumulative probability of parasite qPCR positivity by day 28 was 81% (95% confidence interval [CI], 60.2-91.6). Geometric mean parasitemia at recruitment was 516.1 parasites/μL and fell to <100 parasites/μL by day 3, reaching 56.7 parasites/μL on day 28 (P < .001). The ratio of P. falciparum-positive samples by microscopy to qPCR decreased from 0.9 to 0.52 from recruitment to day 28. The best model fit to the data was obtained assuming a Gompertz distribution. Conclusions: Afebrile P. falciparum infections detectable by RDT in semi-immune adults fall and stabilize at low-density levels during the first 4 days after detection, suggesting a rapid decline of potential transmissibility in this hidden parasite reservoir. Clincial trials registration: NCT02698748.

Indexed as

AdolescentAdultChildFeverHumansMalaria, FalciparumMaleMozambiqueParasitemiaPlasmodium falciparumYoung Adult

Identifiers

PMID29546346
PMCPMC6137111
OpenAlexW2791472063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.